OrbiMed’s Vir Biotechnology VIR Stock Holding History

OrbiMed’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,380,715	Closed	-$14.4M	–	135
2025 Q4	$14.4M	Hold	2,380,715	–	–	0.29%	70
2025 Q3	$13.6M	Hold	2,380,715	–	–	0.33%	65
2025 Q2	$12M	Buy	2,380,715 +132,466	+6%	+$710K	0.3%	55
2025 Q1	$14.6M	Sell	2,248,249 -970,368	-30%	-$8.63M	0.35%	51
2024 Q4	$23.6M	Sell	3,218,617 -354,383	-10%	-$2.8M	0.49%	47
2024 Q3	$26.8M	Buy	3,573,000 +1,252,898	+54%	+$10.9M	0.49%	52
2024 Q2	$20.6M	Buy	2,320,102 +1,680,102	+263%	+$16.1M	0.41%	60
2024 Q1	$6.48M	Buy	640,000 +539,000	+534%	+$5.49M	0.12%	93
2023 Q4	$1.02M	Buy	+101,000	New	+$923K	0.02%	105

Other funds holding VIR

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

GSK plc London $599M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $1.66B AUM 340.85% 1-Year Est. Return